Illinois Tool Works Inc. vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Illinois Tool Works Inc. is far larger — about 43.5× Nuvation Bio Inc. Class A Common Stock's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| ITW | NUVB | |
|---|---|---|
Market Cap | $74.38B | $1.71B |
Volume | 1,125,477 | 5,448,712 |
Sector | Industrials | Health |
52-Week High | $299.60 | $9.54 |
52-Week Low | $241.07 | $3.41 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $83.23B | $1.30B |
Dividend Yield | 2.63% | — |
Signals from Pluang's Aura AI — not financial advice
ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.
Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →